In the BioHarmony Drug Report Database
Siponimod fumaric acid
Mayzent (siponimod fumarate) is a small molecule pharmaceutical. Siponimod fumarate was first approved as Mayzent on 2020-01-13. It has been approved in Europe to treat relapsing-remitting multiple sclerosis.
Trade Name
|
Mayzent |
|---|---|
Common Name
|
siponimod fumarate |
ChEMBL ID
|
CHEMBL4298150 |
Indication
|
relapsing-remitting multiple sclerosis |
Drug Class
|
Immunomodulators |
Image (chem structure or protein)